Narrative
Research at the University of Manchester (UoM) has led a step-change in respiratory care for airway disease from oral to novel inhaled therapies targeted at asthma and chronic obstructive pulmonary disease (COPD) patients worldwide. UoM researchers carried out >250 studies, partnered industry to deliver >15 new inhaled drug formulations to market and were the first to test novel CFC-free inhalers. UoM led the development of global guidelines that influence better diagnosis and management of airways diseases. Through leadership within the Montreal Protocol since 1995, UoM researchers coordinated the safe global transition to CFC-free inhalers for ~200m patients with asthma and COPD, whilst protecting the ozone layer and climate.| Impact date | 2014 |
|---|---|
| Category of impact | Health impacts |
| Impact level | Benefit |
Related content
-
Research output
-
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
Research output: Contribution to journal › Article › peer-review
-
Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD
Research output: Contribution to journal › Article › peer-review
-
Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma
Research output: Contribution to journal › Article › peer-review
-
Susceptibility to exacerbation in chronic obstructive pulmonary disease
Research output: Contribution to journal › Article › peer-review
-
Double-blind trial of steroid tapering in acute asthma
Research output: Contribution to journal › Article › peer-review
-
Impacts
-
Clinical trials in chronic obstructive pulmonary disease (COPD) advancing effective combination treatments
Impact: Health and wellbeing, Economic